Search

Your search keyword '"M. Martin Jimenez"' showing total 66 results
Start Over Author "M. Martin Jimenez"
66 results on '"M. Martin Jimenez"'

1. 114P Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

Author

S. Lopez-Tarruella Cobo, M.A. Pollán, R. Andrés Conejero, M. Martin Jimenez, S. Servitja Tormo, B. Bermejo, A. Anton Torres, A.L. Guerrero Zotano, M. Munoz, L.A. Fernández-Morales, P. Martinez del Prado, I. Alvarez Lopez, L. Calvo-Martinez, A. Rodríguez-Lescure, A. Arcusa Lanza, M. Ruiz Borrego, J. Herranz, O. Polonio, E. Adrover, and C. Jara Sanchez

Subjects
Cancer Research, Oncology
Published
2023
Full Text
View/download PDF

2. 7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer

Author

E. Sanfeliu Torres, G. Villacampa, T. Pascual, M. Oliveira, M.J. Vidal Losada, M. Bellet-Ezquerra, B. Gonzalez-Farre, J.A. Puig-Butille, P. Jares, S. Pernas Simon, C. Bueno Muiño, M. Martin Jimenez, P. Tarantino, A.G. Waks, E.A. Mittendorf, S.M. Tolaney, J. Cortés, A. Llombart Cussac, A. Prat, and F. Brasó-Maristany

Subjects
Cancer Research, Oncology
Published
2023
Full Text
View/download PDF

3. 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies

Author

A.G. Waks, G. Villacampa, L. Pare Brunet, N.M. Tung, C. Bueno Muiño, I. Echavarria Diaz-Guardamino, S. Lopez-Tarruella Cobo, M. Marín-Aguilera, F. Brasó-Maristany, T. Pascual, O. Martinez Saez, A.C. Wolff, A. Demichele, C.M. Perou, A. Fernandez-Martinez, L.A. Carey, E.A. Mittendorf, M. Martin Jimenez, A. Prat, and S.M. Tolaney

Subjects
Cancer Research, Oncology
Published
2023
Full Text
View/download PDF

5. Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status

Author

N. Gutiérrez Alonso, M. Martin Jimenez, P. García Alfonso, M. Bringas Beranek, I Aguilar Caballero, A. Muñoz Martín, L. Ortega Morán, V Tirado Anula, B Morón García, M de Toro Carmena, and J. Soto Alsar

Subjects
Male, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, endocrine system diseases, Colorectal cancer, medicine.disease_cause, GTP Phosphohydrolases, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, cardiovascular diseases, neoplasms, Aged, Retrospective Studies, business.industry, Incidence, Incidence (epidemiology), Membrane Proteins, Venous Thromboembolism, General Medicine, Middle Aged, medicine.disease, Thrombosis, digestive system diseases, 030104 developmental biology, 030220 oncology & carcinogenesis, Mutation, Cohort, Biomarker (medicine), Female, KRAS, Colorectal Neoplasms, business
Abstract

There are conflicting data regarding the role of KRAS mutation on the risk of venous thromboembolism (VTE) in colorectal cancer (CRC) patients. Moreover, the role of other biomarkers such as NRAS or BRAF has not been studied. To analyze the incidence of VTE in a cohort of patients with CRC based on KRAS, NRAS, and BRAF status. We performed a retrospective review of patients with unresectable locally advanced and metastatic CRC (mCRC) and known KRAS/NRAS/BRAF status, attended in the Medical Oncology Department of the Hospital General Universitario Gregorio Maranon (Madrid, Spain). The primary outcome was VTE defined as any venous thromboembolic event that occurred either 6 months before or at any time after the diagnosis of CRC. The biomarker status (KRAS, NRAS, and BRAF) and other predictors of thrombosis were collected. One hundred and ninety-four patients were identified and included in the analysis. Forty-one patients (21.1%) experienced VTE. The incidence was 19.1% in RAS-mutated patients, 28.6% in BRAF-mutated patients and 21% in triple wild-type patients (p = NS). In multivariate analysis, ECOG ≥ 2 was the only independent predictor of VTE (OR 8.73; CI 95% 1.32–57.82; p = 0.025). In our study, biomarkers have not been associated with an increased risk of VTE in CRC patients. A high incidence of VTE in BRAF-mutated patients has been observed and should be explored in further studies.

Published
2020
Full Text
View/download PDF

6. 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

Author

M. Martin Jimenez, E. Lim, M. Chavez Mac Gregor, A. Bardia, J. Wu, Q. Zhang, Z. Nowecki, F. Cruz, R. Safin, S-B. Kim, C. Schem, A. Montero, S. Khan, R. Bandyopadhyay, M. Shivhare, M. Patre, J. Martinalbo, L. Roncoroni, P.D. Pérez-Moreno, and J. Sohn

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

7. 1589P Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)

Author

I. Gonzalez Caraballo, R. Martín Lozano, R. Jiménez Rodríguez, B. Lobato Delgado, M.A. Cañete Muñoz, M. Benavente, M. Palma, M.T. De Toro Carmena, B.I. Morón, V.C. Tirado Anula, J. Soto Alsar, M. Bringas Beranek, N. Gutierrez Alonso, C. López Jiménez, A. Gutiérrez Ortiz de la Tabla, D.S. Juliao Caamaño, L. Ortega Morán, J.M. Soria Fernandez, M. Martin Jimenez, and A.J. Munoz Martin

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

8. 273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788

Author

S.A. Hurvitz, K. Kalinsky, D. Tripathy, G. Sledge, W.J. Gradishar, J. O'Shaughnessy, S. Modi, H. Park, A. McCartney, S. Frentzas, C. Shannon, K. Cuff, R.W. Eek, M. Martin Jimenez, G. Curigliano, G. Jerusalem, C. Huang, M. Press, and J. Lu

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

9. PO-56 Relationship between clinical presentation of SARS-CoV-2 infection and risk of thromboembolic events and prognosis in cancer patients

Author

J. L. Catoya Villa, M. Martin Jimenez, D. S. Juliao Caamaño, C. López Jiménez, C. Blanco Abad, L. Ortega Morán, A. Muñoz Martín, and A. Gutiérrez Ortiz de la Tabla

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Posters, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine, Cancer, Hematology, Presentation (obstetrics), medicine.disease, business, Virology
Published
2021
Full Text
View/download PDF

10. 216P Relationship between regulatory T lymphocytes (Treg): Related genes and pathological response to neoadjuvant docetaxel-carboplatin in early-stage triple-negative breast cancer (TNBC)

Author

R. Martín Lozano, M. Roche-Molina, E. Alvarez, M. Del Monte-Millan, Y. Jerez Gilarranz, F. Moreno Anton, J.Á. García Saenz, I. Echavarria Diaz-Guardamino, T. Massarrah, M. Cebollero, A.I. Ballesteros Garcia, U. Bohn Sarmiento, H.L. Gomez Moreno, H.A. Fuentes, B. Herrero Lopez, S. Gamez Casado, C. Bueno Muiño, O. Bueno, S. Lopez-Tarruella Cobo, and M. Martin Jimenez

Subjects
Oncology, Immunology and Allergy
Published
2022
Full Text
View/download PDF

11. 60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B

Author

J. Furlanetto, F. Marmé, C. Thode, V. Nekljudova, Y. Liu, M. Martin Jimenez, T. Reimer, E. Knudsen, C. Denkert, M. Bassy, L-A. Martin, T. Karn, B.V. Sinn, M. Filipitis, M. van Mackelenbergh, P.A. Fasching, V. Müller, E. Stickeler, C. Schem, and S. Loibl

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

12. 62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials

Author

M. Martin Jimenez, A. Rodríguez-Lescure, R. Andres Conejero, S. Servitja Tormo, A. Anton Torres, M. Ruiz Borrego, B. Bermejo De Las Heras, A. Guerrero, M. Ramos Vazquez, A. Santaballa Bertran, M. Munoz, J.N. Batista, S. Lopez-Tarruella Cobo, J.I. Chacon Lopez-Muniz, I. Alvarez Lopez, M.P. Martinez del Prado, J.J. Miralles, O. Polonio, C. Jara Sanchez, and M. Mori de Santiago

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

13. 141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel

Author

I. Echavarria Diaz-Guardamino, S. Lopez-Tarruella Cobo, M. Del Monte-Millan, E. Alvarez, Y. Jerez, F. Moreno Anton, J.Á. García Saenz, T. Massarrah, I. Ocaña, M. Cebollero, A.I. Ballesteros Garcia, U. Bohn Sarmiento, H. Gomez, H.A. Fuentes, B. Herrero Lopez, S. Gamez Casado, O. Bueno, M.J. Jiménez-Santos, M. Roche-Molina, and M. Martin Jimenez

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

14. Casi ahogamiento en una piscina

Author

Alejandro del Caño Garrido, M. Martin Jimenez, Ana Pascua Aberturas, Rosa Capilla Pueyo, Paula Molina Avila, and Jose Manuel Portal Tocino

Subjects
Medicine (General), R5-920, General Medicine
Published
2021

16. 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

Author

E.P. Hamilton, C.L. Shapiro, V. Boni, M. Martin Jimenez, G. Del Conte, J. Cortés, L. Agrawal, H-T. Arkenau, A.R. Tan, P.R. Debruyne, A.R. Minchom, A. Rutten, F. Valdes-Albini, E. Yu, F. Suto, F-C. Cheng, B. Augustine, B. Cheng, D. Barrios, and S.A. Hurvitz

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

17. LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

Author

P. Neven, P.A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G.V. Bianchi, M. Martin Jimenez, A. Nusch, G.S. Sonke, L. de la Cruz Merino, J.T. Beck, J.P. Zarate, Y. Wang, A. Chakravartty, C. Wang, and D. Slamon

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

19. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

Author

Lourdes Calvo, Miguel Gil-Gil, Emiliano Zamora de Alba, Antonio Antón, J. de la Haba, M. Martin Jimenez, E.M. Ciruelos, M. Ramos, Nicholas C. Turner, Mireia Margeli, Begoña Bermejo, Massimo Corsaro, Montse Muñoz, Tibor Csoszi, Manuel Ruiz-Borrego, Zsuzsanna Kahán, Miquel Casas, Christoph C. Zielinski, Serafin Morales, and Eva Carrasco

Subjects
Oncology, medicine.medical_specialty, biology, business.industry, Endocrine therapy, Hematology, Palbociclib, engineering.material, medicine.disease, Metastatic breast cancer, Capecitabine, Hormone receptor, Internal medicine, medicine, biology.protein, Overall survival, engineering, Aromatase, business, Pearl, medicine.drug
Published
2021
Full Text
View/download PDF

20. Use of antibiotics by spanish dentists receiving postgraduate training in endodontics

Author

José López-López, Oscar Alonso-Ezpeleta, M Martin-Jimenez, Paloma Montero-Miralles, Juan J. Segura-Egea, María del Carmen Jiménez-Sánchez, Jenifer Martín-González, Leopoldo Forner-Navarro, Eugenio Velasco-Ortega, Benjamín Martín-Biedma, and Universitat de Barcelona

Subjects
0301 basic medicine, medicine.medical_specialty, medicine.drug_class, 030106 microbiology, Antibiotics, Dentistry, Antibiòtics, Endodontics, Operative Dentistry and Endodontics, 03 medical and health sciences, 0302 clinical medicine, Antibiotic resistance, Clavulanic acid, medicine, Endodòncia, Medical prescription, Espanya, Periodontitis, General Dentistry, business.industry, Research, Clindamycin, 030206 dentistry, Amoxicillin, Penicillin, Spain, business, medicine.drug
Abstract

Background The incidence of endodontic infections is high. The contribution of Endodontics to the global problem of antibiotic resistance could be significant. The ESE, together with the World Health Organization, are promoting the World Antibiotic Awareness Week (13-19 November 2017) to promote the appropriate use of systemic antibiotics in Endodontics. The objective of this study was to determine the prescription pattern of antibiotics in the treatment of endodontic infections of Spanish dentists attending specialization programs in Endodontics. Material and Methods Dentists from five Spanish endodontic postgraduate programs were requested to answer a one-page questionnaire surveying about antibiotics indications. Seventy-three dentists were required to participate in this investigation, and 67 (91.2%) fulfilled satisfactorily the survey and were included in the study. Data were analyzed using descriptive statistics and chi square test. Results The average duration of antibiotic therapy was 6.8±1.2 days. All respondents chose amoxicillin as first choice antibiotic in patients with no medical allergies, alone (40%) or associated to clavulanic acid (60%). The first drug of choice for penicillin allergic patients was clindamycin (72%). For cases of irreversible pulpitis, 22% of respondents prescribed antibiotics. For the scenario of a necrotic pulp, symptomatic apical periodontitis and no swelling, 37% prescribed antibiotics. A quarter of dentists prescribed antibiotics for necrotic pulps with asymptomatic apical periodontitis and a sinus tract. Conclusions The results of this study show that postgraduate training in Endodontics provides greater awareness of the correct indications of antibiotics. Dentists who have received specialized training in Endodontics have a prescription pattern of antibiotics more adjusted to the guidelines recommended by international organizations and by scientific societies. Key words:Antibiotics, apical periodontitis, dental curriculum, endodontic infections, postgraduate endodontic training.

Published
2018

21. OC-02 Khorana risk score at diagnosis of SARS-CoV-2 infection as a predicting tool for venous thromboembolic disease development, and overall mortality, in cancer patients

Author

C. López Jiménez, A. Muñoz Martín, J. L. Catoya Villa, C. Blanco Abad, D. S. Juliao Caamaño, L. Ortega Morán, M. Martin Jimenez, and A. Gutiérrez Ortiz de la Tabla

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Framingham Risk Score, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Cancer, Hematology, medicine.disease, Venous thromboembolic disease, Oral Communications, Internal medicine, Medicine, business
Published
2021

22. PO-58 Venous and arterial tromboembolic events among hospitalized cancer patients with SARS-COV2 infection

Author

L. O. Moran, M. Martin Jimenez, D. S. J. Caamano, C. L. Jimenez, A. G. O. de la Tabla, J. L. C. Villa, C. B. Abad, and A. M. Martin

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Posters, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Internal medicine, medicine, Cancer, Hematology, medicine.disease, business
Published
2021
Full Text
View/download PDF

23. 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study

Author

M. Ramos, J de la Haba, Manuel Ruiz-Borrego, Antonio Antón, Massimo Corsaro, Miguel Gil-Gil, I. Alvarez-Lopez, M. Margeli Vila, M Casas, Eva Carrasco, E. Gautier, M. Martin Jimenez, E.M. Ciruelos, Montse Muñoz, Christoph C. Zielinski, G. Rodrigálvarez, B. Bermejo De Las Heras, Zsuzsanna Kahán, Einav Nili Gal-Yam, and Lourdes Calvo

Subjects
Oncology, medicine.medical_specialty, business.industry, Endocrine therapy, Hematology, Palbociclib, engineering.material, medicine.disease, Metastatic breast cancer, Capecitabine, Quality of life, Internal medicine, medicine, engineering, business, Pearl, medicine.drug
Published
2020
Full Text
View/download PDF

24. 144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)

Author

Peter A. Fasching, Brad Lanoue, Karen Rodriguez-Lorenc, Patrick Neven, G. Jerusalem, A. Gaur, Manu Sondhi, Arnd Nusch, M. Martin Jimenez, Giancarlo Bianchi, M. De Laurentiis, A. Chan, David Chandiwana, JT Beck, and S Chia

Subjects
Oncology, medicine.medical_specialty, Fulvestrant, business.industry, Advanced breast, First line, Cancer, Ribociclib, Hematology, medicine.disease, Second line, Internal medicine, Medicine, business, medicine.drug
Published
2020
Full Text
View/download PDF

25. New clinical trials regulation in Spain: analysis of royal decree 1090/2015

Author

M. Lázaro Quintela, R Vera García, J. M. Sepulveda Sanchez, A. Santaballa Bertran, A. Calvo Ferrandiz, J. Aparicio Urtasun, J.A. Virizuela Echaburu, M. Muñoz Mateu, Rosario García-Campelo, E. Gonzalez-Flores, M. Martin Jimenez, M. A. Segui Palmer, C. A. Rodríguez Sánchez, [Martin Jimenez, M.] Hosp Univ Gregorio Maranon, Madrid, Spain, [Calvo Ferrandiz, A.] Hosp Univ Gregorio Maranon, Madrid, Spain, [Aparicio Urtasun, J.] Hosp Univ I Politecn la Fe, Valencia, Spain, [Santaballa Bertran, A.] Hosp Univ I Politecn la Fe, Valencia, Spain, [Garcia-Campelo, R.] Complexo Hosp Univ A Coruna, La Coruna, Spain, [Gonzalez-Flores, E.] Hosp Univ Virgen de las Nieves, Granada, Spain, [Lazaro Quintela, M.] Complejo Hosp Univ Vigo, Vigo, Spain, [Munoz Mateu, M.] Hosp Clin I Prov, Barcelona, Spain, [Rodriguez Sanchez, C. A.] Hosp Clin Univ, Salamanca, Spain, [Sepulveda Sanchez, J. M.] Hosp 12 Octubre, Madrid, Spain, [Vera Garcia, R.] Complejo Hosp Navarra Pamplona, Pamplona, Spain, [Virizuela Echaburu, J. A.] Complejo Hosp Reg Virgen Macarena, Seville, Spain, and [Segui Palmer, M. A.] Hosp Sabadell, Consorcio Sanitario Parc Tauli, Sabadell, Spain

Subjects
Conduct, Cancer Research, media_common.quotation_subject, Legislation, Regulation 536/2014, Public administration, Transparency, Special Article, 03 medical and health sciences, Clinical trials, 0302 clinical medicine, Institution, Humans, Medicine, 030212 general & internal medicine, media_common, Clinical Trials as Topic, Non-commercial trials, business.industry, Royal Decree 1090/2015, Timeline, General Medicine, Directive, Transparency (behavior), Clinical trial, Low-intervention clinical trials, Clinical research, Oncology, Spain, 030220 oncology & carcinogenesis, Government Regulation, Medicinal products, Bureaucracy, business
Abstract

The coming into force of Directive 2001/20/EC represented a step forward in harmonising clinical trial regulation in European countries, guaranteeing a uniform protection of subjects participating in clinical research across Europe. However, it led to a disproportionate increase in the bureaucratization, and thus, it became evident that procedures needed to be simplified without detriment to patient’s safety. Thus, Regulation 536/2014, that repealed Directive 2001/20/EC, with the aim of decreasing the growing bureaucratization and stimulating clinical research in Europe, established simplified procedures, such as regulating a common procedure for authorising trials in Europe, the institution of strict assessment timelines, or the definition of new concepts, such as “low-intervention clinical trial”. The legal form of a Regulation allowed the norm to be directly applied to Member States without the need for transposition. By means of the new Royal Decree, the national legislation is adapted to make the application of the regulation feasible and it allows the development of the aspects that the Regulation leaves to national legislation. Both documents seek to stimulate clinical research with medicinal products to foster knowledge, facilitate transparency, and reinforce subjects’ safety. This will surely be the case, but with this revision, we will look at the novelties and key aspects that are most relevant to investigators and we will analyse the consequences for all parties involved in clinical research.

Published
2016
Full Text
View/download PDF

26. 142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial

Author

JT Beck, G. Jerusalem, Patrick Neven, Brad Lanoue, Peter A. Fasching, M. Martin Jimenez, Thomas E. Delea, S-A. Im, Arnd Nusch, A. Lonshteyn, M. De Laurentiis, A. Chan, and David Chandiwana

Subjects
Oncology, medicine.medical_specialty, Postmenopausal women, Fulvestrant, business.industry, Advanced breast, Cancer, Ribociclib, Hematology, medicine.disease, Placebo, Internal medicine, Medicine, Quality adjusted survival, business, medicine.drug
Published
2020
Full Text
View/download PDF

27. 23P Clinical, pathological and gene expression features of HER2-low breast cancer

Author

Aranzazu Fernandez-Martinez, Giuseppe Perrone, Blanca Gonzalez-Farre, Benedetta Conte, Laia Paré, Esther Sanfeliu, J. Gavila Gregori, Andreu Prat, T. Pascual, Fara Brasó-Maristany, M. Martin Jimenez, B. Adamo, A. Lluch, Patricia Villagrasa, Francesco Schettini, S. De Placido, Olga Martínez-Sáez, Carlos H. Barrios, Nuria Chic, and M.J. Mendez Vidal

Subjects
Breast cancer, Oncology, business.industry, Gene expression, Cancer research, Medicine, Hematology, business, medicine.disease, Pathological
Published
2020
Full Text
View/download PDF

28. 83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes

Author

M. Gnant, M. Martin Jimenez, Janine Mansi, Bo Zhang, Manuel Ruiz-Borrego, Beverly Moy, R. Birhiray, C.K. Osborne, Bent Ejlertsen, Erik Jakobsen, Alvin Wong, and Frankie A. Holmes

Subjects
Oncology, medicine.medical_specialty, business.industry, Treatment duration, Hematology, medicine.disease, Breast cancer, Trastuzumab, Internal medicine, Neratinib, medicine, Adjuvant therapy, Stage (cooking), business, medicine.drug
Published
2020
Full Text
View/download PDF

29. Dental students' knowledge regarding the indications for antibiotics in the management of endodontic infections

Author

José López-López, Benjamín Martín-Biedma, Oscar Alonso-Ezpeleta, Eugenio Velasco-Ortega, Juan J. Segura-Egea, M. C. Jiménez‐Sánchez, and M Martin-Jimenez

Subjects
0301 basic medicine, Male, medicine.medical_specialty, medicine.drug_class, education, 030106 microbiology, Antibiotics, Students, Dental, Dentistry, Asymptomatic, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Clavulanic acid, Surveys and Questionnaires, medicine, Dental Pulp Necrosis, Humans, General Dentistry, Periodontitis, business.industry, Clindamycin, Pulpitis, 030206 dentistry, Amoxicillin, medicine.disease, Endodontics, Anti-Bacterial Agents, Penicillin, Spain, Clinical Competence, medicine.symptom, business, Periapical Periodontitis, medicine.drug
Abstract

Aim To determine the knowledge of undergraduate Spanish dental students regarding the indications of systemic antibiotics in the management of endodontic infections. Methodology The final year dental students from four Spanish dental schools were requested to answer a one-page questionnaire on the indications for systemic antibiotics in the treatment of endodontic infections. One hundred and seventy-five students were asked to participate in this research. Data were analysed using descriptive statistics and chi-square test. Results One hundred and four students (93.7%) completed satisfactorily the survey and were included in the study. The average duration of antibiotic therapy was 7.0 ± 2.0 days. All respondents chose amoxicillin as the first-choice antibiotic in patients with no medical allergies, alone (47%) or associated with clavulanic acid (53%). The first drug of choice for patients with an allergy to penicillin was clindamycin 300 mg (99%). For cases of irreversible pulpitis, up to 63% of students would prescribe antibiotics. For the scenario of a necrotic pulp, symptomatic apical periodontitis and no swelling, 44% would prescribe antibiotics. Almost 40% of students would prescribe antibiotics for necrotic pulps with asymptomatic apical periodontitis and a sinus tract. Conclusions It is necessary for the Spanish schools of dentistry to improve students’ knowledge about antibiotics and their indications in endodontics. Interactive education analysing real endodontic cases using problem-based learning would help students acquire better skills in prescribing antibiotics in pulp–periapical pathosis.

Published
2017

30. Clinical guide SEOM on venous thromboembolism in cancer patients

Author

M. Martin Jimenez, P. Borrega García, C. Font Puig, L. M. Navarro Martín, and A. Muñoz Martín

Subjects
Cancer Research, medicine.medical_specialty, Prognostic factor, business.industry, MEDLINE, Clinical Guides in Oncology, Cancer, Thrombosis, Venous Thromboembolism, General Medicine, Guideline, Guidelines, equipment and supplies, medicine.disease, Anticoagulation, Oncology, Neoplasms, Humans, Medicine, cardiovascular diseases, business, Intensive care medicine, Venous thromboembolism
Abstract

Venous thromboembolism (VTE) is a common event in cancer patients and one of the major causes of cancer-associated mortality and a leading cause of morbidity. In recent years, the incidence rates of VTE have notably increased; however, VTE is still commonly underestimated by oncologists. VTE is considered an adverse prognostic factor in cancer patients in all settings. In 2011 the Spanish Society of Medical Oncology (SEOM) first published a clinical guideline of prophylaxis and treatment of VTE in cancer patients. In an effort to incorporate evidence obtained since the original publication, SEOM presents an update of the guideline for thrombosis and cancer in order to improve the prevention and management of VTE.

Published
2014
Full Text
View/download PDF

31. Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial

Author

Fan Xu, Michael Gnant, Hiroji Iwata, Janine Mansi, Beverly Moy, Robert Šeparović, M. Martin Jimenez, Richard Bryce, Carlos H. Barrios, Suzette Delaloge, Marc Buyse, Bent Ejlertsen, Z Tomasevic, S-W. Kim, Frankie A. Holmes, Erik Jakobsen, A. Chan, S Chia, Neelima Denduluri, and G. von Minckwitz

Subjects
Oncology, medicine.medical_specialty, 030219 obstetrics & reproductive medicine, business.industry, Hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Trastuzumab, 030220 oncology & carcinogenesis, Internal medicine, Neratinib, medicine, Adjuvant therapy, Stage (cooking), business, medicine.drug
Published
2017
Full Text
View/download PDF

32. Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms

Author

Inmaculada Ocaña, M. Ruiz Borrego, M. Martin Jimenez, Javier Gayarre, Tatiana Massarrah, M. del Monte-Millán, I. Echavarria Diaz-Guardamino, Antoni Picornell, R. Ramos Medina, A.I. Ballesteros Garcia, Maria Cebollero, Charles M. Perou, Katherine A. Hoadley, Yolanda Jerez, S. Lopez-Tarruella Cobo, H. Gomez Moreno, Joel S. Parker, JA Garcia-Saenz, E.L. Alvarez Castillo, and F. Moreno Antón

Subjects
Correlation, Oncology, business.industry, Gene expression, Medicine, Cancer, RNA-Seq, Hematology, Computational biology, business, medicine.disease
Published
2017
Full Text
View/download PDF

36. EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)

Author

Peter Schmid, M. Martin Jimenez, S. Mondal, Gabriel N. Hortobagyi, K. Hazell, Stephen Chia, M. Shilkrut, Thomas Bachelot, C. Germa, Sherene Loi, Wolfgang Janni, Bella Kaufman, K. L. Blackwell, Carlos H. Barrios, DJ Slamon, M. De Laurentiis, and Sara A. Hurvitz

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Endocrine therapy, Phases of clinical research, Ribociclib, Hematology, 03 medical and health sciences, 0302 clinical medicine, Hormone receptor, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, Adjuvant, Human Epidermal Growth Factor Receptor 2, Early breast cancer
Published
2017
Full Text
View/download PDF

37. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4)

Author

Inmaculada Ocaña, Javier Gayarre, Yolanda Jerez, Rocío Ramos-Medina, A.I. Ballesteros Garcia, M. Martin Jimenez, U. Bohn Sarmiento, H. Gomez Moreno, Antoni Picornell, Katherine A. Hoadley, Elida Alvarez, Charles M. Perou, Tatiana Massarrah, Maria Cebollero, I. Echavarria Diaz-Guardamino, Hugo Fuentes, Sara López-Tarruella, F. Moreno Antón, M. del Monte-Millán, and JA Garcia-Saenz

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Hematology, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, chemistry, Docetaxel, 030220 oncology & carcinogenesis, Internal medicine, Cohort, medicine, business, Triple-negative breast cancer, medicine.drug
Published
2017
Full Text
View/download PDF

38. Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: A retrospective study in Spanish population

Author

P. Zamora Auñon, N. Martínez Jañez, I. Márquez-Rodas, J.A. García-Saenz, J. A. Guerra Martínez, Y. Izarzugaza Peron, V. Valentín Maganto, L. Manso Sánchez, S. Perez Ramirez, M. Á. Lara Álvarez, F. Moreno Antón, M. Martin Jimenez, M. del Monte-Millán, Sara López-Tarruella, F. Lobo Samper, M. Arroyo Yustos, C. Jara Sánchez, M.J. Echarri González, E.M. Ciruelos Gil, and Yolanda Jerez

Subjects
Spanish population, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Retrospective cohort study, Hematology, Luminal a, business, Recurrence risk
Published
2017
Full Text
View/download PDF

39. Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial

Author

S Chia, H. Iwata, A.H. Auerbach, M. Martin Jimenez, Beverly Moy, Marc Buyse, David Cella, A. Ciceniene, Snezhana Smichkoska, A. Chan, Suzette Delaloge, Janine Mansi, Y. Ye, Frankie A. Holmes, S. Moran, Carlos H. Barrios, Bent Ejlertsen, Lesley Fallowfield, Michael Gnant, and G. von Minckwitz

Subjects
0301 basic medicine, Health related quality of life, Oncology, Gynecology, medicine.medical_specialty, business.industry, Hematology, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, 030220 oncology & carcinogenesis, Internal medicine, Neratinib, medicine, Stage (cooking), business, medicine.drug
Published
2017
Full Text
View/download PDF

40. Tumor microenvironment biomarkers as therapeutic strategies for TNBC

Author

A. Blach, María Sánchez-Aragó, Federico Rojo, Silvia Antolín, M. Ruiz Borrego, Mun N. Hui, JA Garcia-Saenz, Rosalia Caballero, S. Bezares, M.A. Karsdal, M. Martin Jimenez, C.L. Bager, Aurélie Cazet, J.M. Trigo Perez, Sandra A O'Toole, Ander Urruticoechea, L. Pérez-Ramos, and Alexander Swarbrick

Subjects
Tumor microenvironment, Oncology, business.industry, Cancer research, Medicine, Hematology, business, Triple-negative breast cancer
Published
2017
Full Text
View/download PDF

41. CompLEEment-1: Phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC

Author

Katie Zhou, Juan Pablo Zarate, M. De Laurentiis, J. Wu, M. Martin Jimenez, Paul-Henri Cottu, Alistair Ring, and Claudio Zamagni

Subjects
Oncology, medicine.medical_specialty, business.industry, Advanced breast, Letrozole, Endocrine therapy, Cancer, Ribociclib, Hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Hormone receptor, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030212 general & internal medicine, business, medicine.drug, Hormone
Published
2017
Full Text
View/download PDF

42. Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study

Author

A. Anton Torres, Montse Muñoz, Andres Rodriguez Ruiz, M. Martin Jimenez, Beatriz Cirauqui, José Manuel Baena-Cañada, Laura García-Estévez, J. Cruz Jurado, A. Lluch, M. Ramos, E. Alba Conejo, N. Martínez Jañez, Eva Carrasco, Manuel Ruiz-Borrego, S. Del Barco, I. Álvarez López, J.I. Chacon Lopez-Muniz, Silvia Antolín, and Álvaro Rodríguez-Lescure

Subjects
Oncology, medicine.medical_specialty, Postmenopausal women, Fulvestrant, business.industry, 030503 health policy & services, HER2 negative, Hematology, 03 medical and health sciences, 0302 clinical medicine, Anastrozol, Hormone receptor, 030220 oncology & carcinogenesis, Internal medicine, medicine, Adjuvant therapy, 0305 other medical science, business, Early breast cancer, medicine.drug
Published
2017
Full Text
View/download PDF

43. Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial

Author

Maria Angela Aznar, M. Blanco Codesido, S. Martin Algarra, Marisol Quintero, S. Lopez-Tarruella Cobo, R. Álvarez, M. Martin Jimenez, R. Ramos Medina, L. Planelles, A. Calvo Ferrandiz, I. Melero, M.E. Rodriguez Ruiz, Yolanda Jerez, I. Marquez Rodas, E. De Miguel, Javier Gayarre, J.L. Perez Gracia, M. Ponz Sarvise, and Alipio G. Calles

Subjects
0301 basic medicine, business.industry, Cancer, Hematology, First in human, Double stranded rna, medicine.disease, Virology, Clinical trial, 03 medical and health sciences, RNA silencing, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, business
Published
2017
Full Text
View/download PDF

44. Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients

Author

P. Sabin Domínguez, M. Martin Jimenez, Ángela M. Muñoz, C. Lopez, Roberto Vera Alvarez, Tatiana Massarrah, I. Marquez Rodas, A. Calvo Ferrandiz, S. Lopez-Tarruella Cobo, Carmen Rubio, S. Perez Ramirez, Antoni Picornell, B. Puente, M. Herencia, M. Blanco Codesido, Yolanda Jerez, and Alipio G. Calles

Subjects
Pediatrics, medicine.medical_specialty, Oncology, business.industry, Cohort, Medicine, Hematology, Line (text file), business, Prognostic score
Published
2017
Full Text
View/download PDF

45. Worldwide pattern of antibiotics prescription in endodontic infections

Author

J Martin Gonzalez, I Crespo Gallardo, JJ Sauco Marquez, JJ Segura Egea, and M Martin Jimenez

Subjects
0301 basic medicine, 03 medical and health sciences, medicine.medical_specialty, business.industry, medicine.drug_class, 030106 microbiology, Antibiotics, medicine, Dentistry, Medical prescription, Intensive care medicine, business, General Dentistry
Published
2017
Full Text
View/download PDF

49. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model

Author

A. Muñoz Martín, M. Blanco Codesido, S. Perez Ramirez, A.B. Ruperez Blanco, P. García Alfonso, and M. Martin Jimenez

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Platinum Compounds, Neuroendocrine tumors, Deoxycytidine, Risk Assessment, Pancreatic cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, cardiovascular diseases, Gastrointestinal cancer, Aged, Retrospective Studies, Aged, 80 and over, Venous Thrombosis, Models, Statistical, business.industry, Incidence (epidemiology), Incidence, Cancer, Retrospective cohort study, General Medicine, Venous Thromboembolism, Middle Aged, medicine.disease, Gemcitabine, Pulmonary embolism, Pancreatic Neoplasms, Venous thrombosis, Oncology, Female, Radiology, Fluorouracil, business, Pulmonary Embolism, Carcinoma, Pancreatic Ductal
Abstract

To evaluate the incidence of venous thromboembolism (VTE) in ambulatory pancreas cancer patients receiving chemotherapy and analyze Khorana’s predictive model of chemotherapy-associated thrombosis. We performed a retrospective review to determine the incidence of VTE in the gastrointestinal cancer unit of our center. Between 2008 and 2011, 84 consecutives patients diagnosed with pancreas adenocarcinoma were identified and included in the analysis. Pancreatic neuroendocrine tumors were excluded. Thirty patients experienced VTE (35.7 %) and 66 % of the events were diagnosed during the first 6 months after diagnosis. Khorana’s score: 33.3 % of the intermediate category patients developed a venous thromboembolic event and 37.5 % in the high-risk category. The high incidence of VTE observed in this study is consistent with prior reports. Specific predictive model for chemotherapy-associated thrombosis in pancreatic cancer must be investigated.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results